Spontaneous and induced tolerance for liver transplant recipients

Current Opinion in Organ Transplantation

Volumn 21, Issue 1, 2016, Pages

  Feng, Sandy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular therapy; Immunosuppression withdrawal; Liver transplantation; Tolerance

Indexed keywords

ALLOGRAFT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LONG TERM SURVIVAL; MULTICENTER STUDY; RECIPIENT; REGULATORY T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

IMMUNOSUPPRESSIVE AGENT;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84953637289     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000268     Document Type: Review

References (51)

1. Calne RY. Immunological tolerance: the liver effect. Immunol Rev 2000; 174:280-282.
2. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223:472-476; Epub 1969/08/02.
3. Calne RY, White HJ, Yoffa DE, et al. Prolonged survival of liver transplants in the pig. Br Med J 1967; 4:645-648.
4. Kawai T, Sachs DH, Sykes M, Cosimi AB. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2013; 368:1850-1852.
5. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
6. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:124ra28.
7. Scandling JD, Busque S, Shizuru JA, et al. Induced immune tolerance for kidney transplantation. N Engl J Med 2011; 365:1359-1360.
8. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-368.
9. Pilat N, Hock K, Wekerle T. Mixed chimerism through donor bone marrow transplantation: a tolerogenic cell therapy for application in organ transplantation. Curr Opin Organ Transplant 2012; 17:63-70.
10. Crispe IN. Liver antigen-presenting cells. J Hepatol 2011; 54:357-365.
11. Crispe IN. Immune tolerance in liver disease. Hepatology 2014; 60:2109-2117; Epub 2014/06/11.
12. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmunity 2010; 34:1-6.
13. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486-499.
14. Assy N, Adams PC, Myers P, et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of urso-deoxycholic acid. Transplantation 2007; 83:1571-1576.
15. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58:1824-1835.
16. de la Garza RG, Sarobe P, Merino J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transplant 2013; 19:937-944.
17. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immuno-suppression withdrawal after liver transplantation. Hepatology 1998; 27:926-933.
18. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk? Transplantation 2005; 79:1157-1159.
19. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunol 2007; 17:94-97.
20. Lee JH, Lee SK, Lee HJ, et al. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J 2009; 50:784-788.
21. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transplant Immunol 2007; 17:114-119.
22. Orlando G, Manzia T, Baiocchi L, et al. The Tor Vergata weaning off immuno-suppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transplant Immunol 2008; 20 (1-2):43-47.
23. Pons JA, Yelamos J, Ramirez P, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003; 75:1045-1047.
24. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59:212-217.
25. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosup-pression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44:702-709.
26. Tryphonopoulos P, Tzakis AG, Weppler D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotrans-plantation. Am J Transplant 2005; 5:608-613.
27. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307:283-293.
28. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.
29. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
30. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122:368-382.
31. Bonaccorsi-Riani E, Danger R, Lozano JJ, et al. Iron deficiency impairs intra-hepatic lymphocyte mediated immune response. PLoS One 2015; 10:e0136106.
32. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196:147-160; Epub 2003/11/18.
33. Goldstein DR. Inflammation and transplantation tolerance. Semin Immuno-pathol 2011; 33:111-115.
34. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol 2007; 15:143-146.
35. Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 2014; 146:1193-1207.
36. Bohne F, Londono MC, Benitez C, et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Sci Transl Med 2014; 6:242ra81.
37. Thorp EB, Stehlik C, Ansari MJ. T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant 2015; 20:37-42.
38. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transplant 2006; 12:1523-1528.
39. Donckier V, Troisi R, Toungouz M, et al. Donor stem cell infusion after nonmyeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transplant Immunol 2004; 13:139-146.
40. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702.
41. Calne RY. Prope tolerance: a step in the search for tolerance in the clinic. World J Surg 2000; 24:793-796.
42. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-1510.
43. Benitez CE, Puig-Pey I, Lopez M, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10:2296-2304.
44. Donckier V, Craciun L, Miqueu P, et al. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin. Transplantation 2013; 96:306-315.
45. Donckier V, Craciun L, Lucidi V, et al. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. Transplantation 2009; 87 (9 Suppl):S91-S95.
46. Bashuda H, Kimikawa M, Seino K, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 2005; 115:1896-1902.
47. Davies JK, Barbon CM, Voskertchian A, et al. Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant 2012; 21:2047-2061.
48. Davies JK, Yuk D, Nadler LM, Guinan EC. Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation 2008; 86:854-864.
49. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340:1704-1714.
50. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13:3010-3020.
51. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harbor Perspect Med 2013; 3:; pii: a015552.